Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

Following the latest results AbbVie has its sights on FDA and European filings for risankizumab, although Johnson & Johnson already has an IL-23 blocker, Tremfya (guselkumab) recently approved in ...

such as J&J's own Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), and Sun Pharma’s Ilumya (tildrakizumab). FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

Oct. 24, 2024 — Lithium-sulfur batteries have never lived up to their potential as the next generation of renewable batteries for electric vehicles and other devices. But mechanical engineers ...

Western officials are investigating whether devices planted at shipping hubs in Europe may have been a test run by Russian operatives for placing them on planes bound for the U.S. By Michael ...